Day 15 bone marrow minimal residual disease predicts response to blinatumomab in relapsed/refractory paediatric B‐ALL

Haematology, 154, 477–481. Czuczman, M.S., Trneny, M. , Davies, A. , Rule, S. , Linton, K.M. , Wagner-Johnston, N. , Gascoyne, R.D. , Slack, G.W. , Brousset, P., Eberhard, D.A. , Hernandez-Ilizaliturri, F.J., Salles, G. , Witzig, T.E. , Zinzani, P.L. , Wright, G.W. , Staudt, L.M. , Yang, Y. , Williams, P.M. , Lih, C.J., Russo, J., Thakurta, A. , Hagner, P., Fustier, P., Song, D. & Lewis, I.D. (2017) A phase 2/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator’s choice in patients with relapsed or refractory diffuse large B-cell lymphoma. Clinical Cancer Research, 23, 4127–4137. Gribben, J.G. , Fowler, N. & Morschhauser, F. (2015) Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma. Journal of Clinical Oncology, 33, 2803–2811. Hans, C.P., Weisenburger, D.D. , Greiner, T.C. , Gascoyne, R.D. , Delabie, J., Ott, G. , M€ uller-Hermelink, H.K. , Campo, E. , Braziel, R.M. , Jaffe, E.S. , Pan, Z. , Farinha, P., Smith, L.M. , Falini, B. , Banham, A.H. , Rosenwald, A. , Staudt, L.M. , Connors, J.M. , Armitage, J.O. & Chan, W.C. (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 103, 275–282. Leonard, J.P., Trneny, M. , Izutsu, K. , Fowler, N.H. , Hong, X. , Zhu, J., Zhang, H. , Offner, F. , Scheliga, A. , Nowakowski, G.S. , Pinto, A. , Re, F. , Fogliatto, L.M. , Scheinberg, P., Flinn, I.W. , Moreira, C. , Cabec adas, J., Liu, D. , Kalambakas, S. , Fustier, P., Wu, C. & Gribben, J.G. (2019) AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. Journal of Clinical Oncology, 37, 1188–1199. Nowakowski, G.S. , Hong, F. , Scott, D.W. , Macon, R. , King, R.L. , Habermann, T.M. , WagnerJohnston, N. , Casulo, C. , Wade, J.L. , Nagargoje, G.G. , Reynolds, C.M. , Cohen, J.B. , Khan, N. , Amengual, J., Richards, K.L. , Little, R.F. , Leonard, J.P., Friedberg, J.W. , Kostakoglu, L. , Kahl, B.S. & Witzig, T.E. (2019) Addition of lenalidomide to R-CHOP (R2CHOP) improves outcomes in newly diagnosed diffuse large B-cell lymphoma (DLBCL): first report of ECOGACRIN1412 a randomized phase 2 US intergroup study of R2CHOP vs R-CHOP. Hematological Oncology, 37, 37–38. Schmitz, R. , Wright, G.W. , Huang, D.W. , Johnson, C.A. , Phelan, J.D. , Wang, J.Q. , Roulland, S. , Kasbekar, M. , Young, R.M. , Shaffer, A.L. , Hodson, D.J., Xiao, W. , Yu, X. , Yang, Y. , Zhao, H. , Xu, W. , Liu, X. , Zhou, B. , Du, W. , Chan, W.C. , Jaffe, E.S. , Gascoyne, R.D. , Connors, J.M. , Campo, E. , Lopez-Guillermo, A. , Rosenwald, A. , Ott, G. , Delabie, J., Rimsza, L.M. , Tay Kuang Wei, K. , Zelenetz, A.D., Leonard, J.P., Bartlett, N.L. , Tran, B. , Shetty, J., Zhao, Y. , Soppet, D.R. , Pittaluga, S. , Wilson, W.H. & Staudt, L.M. (2018) Genetics and pathogenesis of diffuse large B-cell lymphoma. New England Journal of Medicine, 378, 1396–1407. Thieblemont, C. , Tilly, H. , Gomes Da Silva, M. , Casasnovas, R.O. , Fruchart, C. , Morschhauser, F. , Haioun, C. , Lazarovici, J., Grosicka, A. , Perrot, A. , Trotman, J., Sebban, C. , Caballero, D. , Greil, R. , Van Eygen, K. , Cohen, A.M., Gonzalez, H. , Bouabdallah, R. , Oberic, L. , Corront, B. , Choufi, B. , Lopez-Guillermo, A. , Catalano, J., Van Hoof, A. , Briere, J., Cabecadas, J., Salles, G. , Gaulard, P., Bosly, A. & Coiffier, B. (2017) Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Journal of Clinical Oncology, 35, 2473–2481. Vitolo, U. , Witzig, T.E. , Gascoyne, R.D. , Scott, D.W. , Zhang, Q. , Jurczak, W. , € Ozcan, M. , Hong, X. , Zhu, J., Jin, J., Belada, D. , Bergua, J.M. , Piazza, F. , M ocikova, H. , Molinari, A.L. , Yoon, D.H. , Cavallo, F. , Tani, M. , Izutsu, K. , Kato, K. , Czuczman, M. , Hersey, S. , Kilcoyne, A. , Russo, J., Hudak, K. , Zhang, J., Chiappella, A. , Nowakowski, G.S. & Investigators, O.B. O.T. R.S. (2019) ROBUST: first report of phase III randomized study of lenalidomide/R-CHOP (R2-CHOP) vs placebo/R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. Hematological Oncology, 37, 36–37. Vose, J.M. , Habermann, T.M. , Czuczman, M.S., Zinzani, P.L. , Reeder, C.B. , Tuscano, J.M. , Lossos, I.S. , Li, J., Pietronigro, D. & Witzig, T.E. (2013) Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation. British Journal of Haematology, 162, 639–647. Wang, M. , Fowler, N. , Wagner-Bartak, N. , Feng, L. , Romaguera, J., Neelapu, S.S. , Hagemeister, F. , Fanale, M. , Oki, Y. , Pro, B. , Shah, J., Thomas, S. , Younes, A. , Hosing, C. , Zhang, L. , Newberry, K.J., Desai, M. , Cheng, N. , Badillo, M. , Bejarano, M. , Chen, Y. , Young, K.H. , Champlin, R. , Kwak, L. & Fayad, L. (2013) Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia, 27, 1902–1909. Witzig, T.E. , Vose, J.M. , Zinzani, P.L. , Reeder, C.B. , Buckstein, R. , Polikoff, J.A. , Bouabdallah, R. , Haioun, C. , Tilly, H. , Guo, P., Pietronigro, D. , Ervin-Haynes, A.L. & Czuczman, M.S. (2011) An international phase II trial of singleagent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Annals of Oncology, 22, 1622–1627.